Chronic Immune Thrombocytopenia With Insufficient Response To Previous Treatment Therapeutics
1. Doptelet patent expiration
Treatment: Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure; Treatment of thrombocytopenia in an adult patient with chronic immune thrombocytop...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7638536 | AKARX INC | 2-Acylaminothiazole derivative or salt thereof |
Jul, 2027
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765764 | AKARX INC | 2-acylaminothiazole derivative or salt thereof |
Jan, 2023
(2 years ago) | |
| US8338429 | AKARX INC | 2-acylaminothiazole derivative or salt thereof |
Jun, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-802) | Jun 26, 2022 |
| New Chemical Entity Exclusivity(NCE) | May 21, 2023 |
| Orphan Drug Exclusivity(ODE-246) | Jun 26, 2026 |
| New Indication(I-974) | Jul 24, 2028 |
Drugs and Companies using AVATROMBOPAG MALEATE ingredient
NCE-1 date: 21 May, 2022
Market Authorisation Date: 21 May, 2018
Dosage: TABLET
More Information on Dosage
DOPTELET family patents
